FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma By Ogkologos - October 19, 2026 11 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results of the RASolute 302 study Source RELATED ARTICLESMORE FROM AUTHOR Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship EMA Recommends Granting a Marketing Authorisation for Senaparib MOST POPULAR 6 Things That Helped Me Think Positively During Cancer: A Patient... August 16, 2022 Survivorship and Immune Checkpoint Inhibitors July 21, 2020 Patient Guide in Prostate Cancer Now Available in Vietnamese December 10, 2025 Three Brothers Under The Age Of 6 Are All Fighting The... February 7, 2020 Load more HOT NEWS Robin Williams Required Film Companies He Worked With To Hire Homeless... Women Experience More Side Effects from Pelvic Radiation than Realized FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma This 11-Year-Old Is Starting College Next Year With A Plan To...
